Wang K, et al. - Given that a chemopreventive action of statins against prostate cancer (PCa) has been suggested by conflicting evidence, researchers investigated if the link of statin use with PCa risk is Gleason score-dependent, time-, dose-respondent. They utilized longitudinal data of electronic medical records from 1994 to 2016 to perform a cohort analysis at a tertiary hospital in the Southeastern US. They analyzed only cancer-free men aged > 18 years at baseline who were observed for ≥ 12 months. A median follow-up of 6.6 years was performed, revealing a diagnosis of PCa in 2,976 of 13,065 men. Findings are suggestive of a possible link of statin use with decreased PCa risk only when used for a relatively longer duration. For PCa of higher Gleason score, a higher risk reduction was noted.